Our previous study 2 using limited 5% Medicare data reported an 11.3% reintervention rate at 90 days and a 33% rate at 5 years. In a 5-year follow-up study of patients implanted with SNM for overactive bladder, Siegel et al 6 also reported only a 67% therapeutic success rate. We extend these results in, to our knowledge, the first large-scale, all-inclusive statewide study demonstrating high SNM device failure. We found that device malfunction was the second most common indication for early reinterventions and the predominant indication at 5 years. Moreover, our results demonstrate that even in the hands of high-volume surgeons, the invasive surgical reintervention rate remains very high. Limitations include generalizability to the entire US population, despite inclusion of all ages and data from all of New York, with its diverse population and practices. Use of billing codes may introduce some misclassification but is a valid method, particularly for reinterventions.
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. Arthroscopic partial meniscectomy-only procedures were identified by CPT codes 29880 (medial and lateral meniscus) and 29881 (medial or lateral meniscus). We defined low-volume surgeons as those performing 10 or fewer arthroscopies annually in the Medicare population (Johns Hopkins University institutional review board approval 00085313). Informed consent was waived for this study due to it being a database study.
Results | We identified 121 624 knee arthroscopies in the Medicare population performed by 12 504 surgeons. We found wide practice variation in the national distribution of surgeons by the proportion of knee arthroscopies they performed that were APM-only procedures, regardless of the indication ( Figure) . Discussion | These data suggest a significant and troubling disparity between evidence and practice for one of the most common operations performed in the United States. There may be a few reasons for this disparity. First, a consumerist culture may be demanding the procedure (also referred to by patients as a "knee washout" or "meniscus shaving"). Patients may perceive a clinical improvement despite unequivocal scientific evidence to the contrary in middle-aged patients with degenerative meniscal lesions. 5 Second, the evidence may be in the slow-adoption phase because of the publication of multiple randomized clinical trials on this topic in recent years. 2 This delay may have 3 contributors: (1) a lack of knowledge about the evidence, (2) knowledge of the evidence but disagreement about the interpretation of findings, or (3) knowledge of the evidence but disregard of the findings. The high safety of this routine procedure may further propagate its overuse. Notably, this study was performed in Medicare patients, suggesting that it underestimates the true magnitude of overuse in the United States. One limitation is coding accuracy. Some surgeons may code for an APM-only procedure when a chondroplasty is actually performed (CPT codes 29877 and 29879). Similarly, surgeons may be coding for an acute meniscal tear in older patients when they really have degenerative disease. Finally, in observing the mass overuse of APM, it is important that we not make absolute conclusions for all patients. The clear lack of benefits from APM in the literature reviewed was exclusively demonstrated in middle-aged and older patients who had developed degenerative meniscal tears.
3,4 Arthroscopic partial meniscectomies may benefit a very small subset of acute traumatic meniscal tears in younger patients, a distinct entity that is different from degenerative meniscal lesions that are common in older patients. Interestingly, a secondary post hoc analysis with 2-year follow-up of the FIDELITY trial 2 rejected the conventional notion that the presence of mechanical symptoms that are associated with unstable meniscal tears represents an absolute indication for surgery, as this sham surgery-controlled randomized clinical trial revealed no benefit from APM over conservative treatments in this selected subgroup. 6 We propose that the annual proportion of knee arthroscopy procedures that are APM-only in patients with degenerative disease is a surgeon-level measure of appropriateness in surgical care. At best, APM represents low-value care that is common in the Medicare population. In considering this quality measure, we believe that a distinction should be made between interventions that lack supporting evidence and practices like APM for degenerative disease that are contrary to ample level 1A evidence. 
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Myocardial Infarction After Vascular Surgery: A Systematic Troponin Surveillance and a Uniform Definition Is Needed
To the Editor The article by Juo et al 1 addresses the important issue of temporal trends in perioperative myocardial infarction after high-risk vascular surgery. We congratulate the authors on their contribution; however, we have some reservations concerning the methods of this study. Definitions of myocardial infarction used in the database are out of date in light of recent developments in perioperative cardiac monitoring. The diagnostic threshold for myocardial infarction in the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) cohort was defined as new elevation in troponin values greater than 3 times the upper level of the reference range. Furthermore, troponin levels were not measured routinely but only when the clinicians suspected ischemia. The problem with this approach is that 65% of perioperative myocardial infarctions are asymptomatic. 
